Abiopharma

🔍 HARPER MICHAEL S (Executive)

Company: zSpace, Inc. (ZSPC)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 17,000 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 55,397.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 17,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 68,000.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Acquired 136,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 204,000.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2, F2

Footnotes:

• F1: On April 1, 2025, the reporting person was awarded the Restricted Stock Units (the "RSUs") reported herein, which RSUs vested into shares of Common Stock on April 1, 2026. Such RSUs were granted to the reporting person by the board of directors of the Company pursuant to the Company's 2024 Equity Incentive Plan.
• F2: The RSUs reported herein shall vest in four (4) equal quarterly installments, commencing on July 1, 2026, and continuing on the same calendar day of each successive quarter thereafter (each a "Vesting Date"), provided that the reporting person remains in continuous service with the Company through each applicable Vesting Date. The number of shares vesting on each Vesting Date shall be equal to 25.0% of the total number of shares subject to this award, rounded to the nearest whole share such that the entire grant will be vested after one (1) year. Such RSUs were granted to the reporting person by the board of directors of the Company pursuant to the Company's 2024 Equity Incentive Plan.
• REMARKS: Chief Product, Engineering and Marketing Officer